Amisulpride-induced tardive dyskinesia.

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Tardive dyskinesia (TD) is a neurological disorder characterized by involuntary movements, often a side effect of long-term antipsychotic medication.
• Schizophrenia treatment frequently involves neuroleptic agents, increasing the risk of developing TD.
• Amisulpride is an antipsychotic medication used for schizophrenia, and its potential to induce TD requires careful monitoring.

Observation:

• A 34-year-old male patient with schizophrenia, disorganized type, experienced significant improvement with amisulpride (400 mg daily).
• After 20 months of treatment, the patient developed TD, presenting with choreiform and athetotic movements.
• The TD symptoms resolved almost completely upon switching the antipsychotic medication to quetiapine (1200 mg).

Findings:

• This case represents the first reported instance of tardive dyskinesia induced by amisulpride.
• The successful resolution of TD after switching to quetiapine suggests a potential link between amisulpride and TD development in this patient.
• The findings highlight the importance of recognizing and managing TD in patients treated with amisulpride.

Implications:

• Clinicians should be vigilant for TD symptoms in patients prescribed amisulpride, even with initial therapeutic success.
• Switching to an alternative antipsychotic, such as quetiapine, may be an effective strategy for managing amisulpride-induced TD.
• Further research is warranted to elucidate the specific mechanisms by which amisulpride may induce TD and to establish prevalence rates.